Clinical Trials Browser

INDUSTRY × Interventional × CB-839 × Clear all

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02771626 2023-03-17

Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Terminated

118 enrolled 18 charts

DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT03057600 2022-09-28

Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)

Phase 2 Completed

52 enrolled 16 charts

Breast

Triple Negative Breast Neoplasms

NCT04265534 2022-09-21

KEAPSAKE

Phase 2 Terminated

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03965845 2022-09-19

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

Phase 1/2 Completed

53 enrolled

Other solid neoplasmThoracic

Solid Tumors

NCT03163667 2022-09-15

ENTRATA

Phase 2 Completed

69 enrolled 12 charts

Genitourinary

Carcinoma, Renal Cell

NCT02071862 2022-07-20

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Phase 1 Completed

210 enrolled

BreastGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mesothelioma, Triple Negative Breast Neoplasms

NCT03875313 2022-02-17

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Phase 1/2 Terminated

33 enrolled 14 charts

BreastGastrointestinalGenitourinary

Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02071888 2018-07-18

Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

Phase 1 Completed

25 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma

NCT02071927 2017-02-09

Study of the Glutaminase Inhibitor CB-839 in Leukemia

Phase 1 Completed

43 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

CANTATA

Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)

KEAPSAKE

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

ENTRATA

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

Study of the Glutaminase Inhibitor CB-839 in Leukemia